Your browser doesn't support javascript.
loading
A phase II trial of lanreotide for the prevention of postoperative pancreatic fistula.
Pillarisetty, Venu G; Abbasi, Arezou; Park, James O; Sham, Jonathan G.
Affiliation
  • Pillarisetty VG; Hepatopancreatobiliary Surgery, University of Washington, Seattle WA, USA. Electronic address: vgp@uw.edu.
  • Abbasi A; Hepatopancreatobiliary Surgery, University of Washington, Seattle WA, USA.
  • Park JO; Hepatopancreatobiliary Surgery, University of Washington, Seattle WA, USA.
  • Sham JG; Hepatopancreatobiliary Surgery, University of Washington, Seattle WA, USA.
HPB (Oxford) ; 24(11): 2029-2034, 2022 11.
Article in En | MEDLINE | ID: mdl-35953409
BACKGROUND: Clinically relevant postoperative pancreatic fistula (CR-POPF) is a significant contributor to morbidity after pancreatectomy. Somatostatin analogues have shown variable efficacy in the prevention of CR-POPF. Lanreotide is a somatostatin analogue ideally suited for perioperative use due to its long half-life and favorable side effect profile. METHODS: We conducted a phase II single-arm trial of a single dose of preoperative lanreotide (120 mg) in patients undergoing either pancreaticoduodenectomy (PD) or distal pancreatectomy (DP). The primary outcome was development of CR-POPF or intra-abdominal abscess. Secondary outcomes included biochemical leak and overall morbidity. RESULTS: A total of 98 patients completed the study. Sixty-two underwent PD (63.3%) and 36 underwent DP (36.7%). The primary outcome was observed in eight (8%) patients in the overall cohort, one from the DP group and seven from the PD group. Biochemical leak was detected in 12 (12.2%) patients in the overall cohort. Twenty-seven (27.5%) patients developed complications, of which 14 (14.2%) were major complications. Drug-related adverse events were limited to mild skin reactions in two (2%) patients. CONCLUSION: Patients who received preoperative lanreotide developed CR-POPF at rates significantly lower than historical controls or published literature. This provides strong justification for a randomized controlled trial.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Postoperative Complications / Somatostatin / Pancreatic Fistula Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: HPB (Oxford) Journal subject: GASTROENTEROLOGIA Year: 2022 Document type: Article Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Postoperative Complications / Somatostatin / Pancreatic Fistula Type of study: Etiology_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: HPB (Oxford) Journal subject: GASTROENTEROLOGIA Year: 2022 Document type: Article Country of publication: United kingdom